<DOC>
	<DOCNO>NCT00425945</DOCNO>
	<brief_summary>The purpose study investigate efficacy Flavangenol® ( Toyo Shinyaku , Japan ) , pine bark extract , lower blood pressure improve glycemic control plasma lipoprotein profile .</brief_summary>
	<brief_title>Understanding Pine Bark Extract Alternative Treatment ( UPBEAT ) Study</brief_title>
	<detailed_description>Cardiovascular disease number one cause death Unites States . Our study test efficacy pine bark extract improve number cardiovascular disease risk factor . We conduct randomize , placebo-controlled , double-blind , parallel trial investigate efficacy safety Flavangenol® ( Toyo Shinyaku , Japan ) , pine bark extract , among 130 study participant . These participant individual mildly moderately elevate risk cardiovascular disease ( CVD ) prehypertension , excess body weight , insulin insensitivity . We aim determine ( order priority ) : 1 . The efficacy Flavangenol lower blood pressure . 2 . The efficacy Flavangenol improve glycemic control plasma lipoprotein profile . 3 . Changes body weight , antioxidative capacity , anti-inflammatory marker , blood coagulation factor , liver function test response Flavangenol . 4 . The safety Flavangenol , confirmation past study .</detailed_description>
	<mesh_term>Pycnogenols</mesh_term>
	<criteria>Systolic blood pressure 125 159 mmHg diastolic blood pressure ( DBP ) &lt; 100 mmHg Body mass index ( BMI ) 25.034.9 Triglycerides ( TG ) &lt; 450 mg/dL Low Density Lipoprotein ( LDL ) &lt; 200 mg/dL Fasting blood glucose ( FBG ) &lt; 126 mg/dL DBP &gt; 95 mmHg LDL &gt; 170 mg/dL TG &gt; 300 mg/dL FBG &gt; 110 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>